Qualigen Therapeutics, Inc. (QLGN)
Largest Insider Buys in Sector
QLGN Stock Price History Chart
QLGN Stock Performance
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based …
Insider Activity of Qualigen Therapeutics, Inc.
Over the last 12 months, insiders at Qualigen Therapeutics, Inc. have bought $0 and sold $0 worth of Qualigen Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Qualigen Therapeutics, Inc. have bought $37,367 and sold $124,085 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $17,100 was made by Poirier Michael S. (Chairman and CEO) on 2022‑06‑22.
List of Insider Buy and Sell Transactions, Qualigen Therapeutics, Inc.
| 2022-06-22 | Chairman and CEO | 30,000 0.0839% | $0.57 | $17,100 | -74.26% | |||
| 2022-06-14 | President/CSO | 30,000 0.0874% | $0.62 | $18,600 | -74.91% | |||
| 2021-08-19 | director | 8,000 0.0272% | $1.23 | $9,800 | -41.03% | |||
| 2021-04-26 | EVP, Chief Strategy Officer | 4,500 0.0141% | $2.03 | $9,135 | -45.98% | |||
| 2021-04-20 | Chairman, CEO & President | 11,005 0.0379% | $1.80 | $19,809 | -31.49% | |||
| 2021-04-16 | Vice President of Finance, CFO | 2,700 0.0096% | $1.86 | $5,022 | -30.77% | |||
| 2020-12-29 | director | 4,000 0.0138% | $2.94 | $11,740 | -39.37% | |||
| 2020-11-23 | director | 4,600 0.0169% | $3.46 | $15,925 | -41.62% | |||
| 2020-11-20 | director | 1,400 0.005% | $3.55 | $4,969 | -44.92% | |||
| 2020-03-12 | Sale | director | 500,000 0.1573% | $0.22 | $110,000 | -18.19% | ||
| 2020-03-04 | Sale | COB, CSO | 18,750 0.005% | $0.38 | $7,043 | -58.01% | ||
| 2020-03-04 | Sale | CEO and President | 18,750 0.005% | $0.38 | $7,043 | -58.01% | ||
| 2018-08-17 | director | 19,751 0.0067% | $2.04 | $40,292 | -53.31% | |||
| 2017-10-03 | 10 percent owner | 5M 0.1754% | $0.40 | $2M | -18.09% | |||
| 2017-10-03 | 5M 0.1754% | $0.40 | $2M | -18.09% | ||||
| 2017-10-03 | Exec. Chairman, CSO | 187,500 0.0066% | $0.40 | $75,000 | -18.09% | |||
| 2017-10-03 | President | 187,500 0.0066% | $0.40 | $75,000 | -18.09% | |||
| 2017-05-18 | director | 18,000 0.0006% | $0.62 | $11,155 | -45.98% | |||
| 2017-05-11 | CEO | 13,000 0.0004% | $0.62 | $8,007 | -43.56% | |||
| 2017-02-27 | CEO | 10,000 0.0003% | $2.65 | $26,480 | -80.14% |
Insider Historical Profitability
| Javelin Venture Partners, L.P. | 10 percent owner | 7047804 957.0217% | $4.04 | 2 | 0 | |
| Doyle Noah | director | 704780 95.7021% | $4.04 | 2 | 1 | |
| Poirier Michael S. | Chairman and CEO | 199202 27.0497% | $4.04 | 2 | 0 | |
| Ritter Andrew J | CEO and President | 81727 11.0977% | $4.04 | 2 | 1 | |
| Ritter Ira E. | COB, CSO | 81727 11.0977% | $4.04 | 2 | 1 |